Search Results - "Freimer M"

SOME NEW RESULTS ON COMPROMISE SOLUTIONS FOR GROUP DECISION PROBLEMS.

Authors: Freimer, M. Yu, P. L.

Source: Management Science (INFORMS). Feb1976, Vol. 22 Issue 6, p688-693. 6p.

503P Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: an interim analysis of RAISE-XT.

Authors: Boroojerdi, B. Freimer, M. Genge, A. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

An Antibody--Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

Authors: Johnson, N. E. Tai, L.-J. Hame, J. I. et al.

Source: New England Journal of Medicine. 2/19/2026, Vol. 394 Issue 8, p763-772. 10p.

Paradoxical sedation with sertraline.

Authors: Gupta, S Freimer, M Popli, A

Source: American Journal of Psychiatry. Sep93, Vol. 150 Issue 9, p1427-1428. 2p.

Trichotillomania, clomipramine, topical steroids.

Authors: Gupta, S Freimer, M

Source: American Journal of Psychiatry. Mar93, Vol. 150 Issue 3, p524-524. 1p.

17PINSPIRE-IBM: an NIH-funded, two-year, multicenter, observational study in inclusion body myositis- an update and AE/SAE reporting.

Authors: Hernandez, I. Wencel, M. Goyal, N. et al.

Source: Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p.

16PComparative evaluation of respiratory assessments in inclusion body myositis from INSPIRE-IBM study.

Authors: Hernandez, I. Wencel, M. Goyal, N. et al.

Source: Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p.

564P Investigating motor and bulbar severity in NT5c1A seropositive and seronegative IBM participants in the INSPIRE-IBM trial.

Authors: Herrera, M. Wencel, M. Hernandez, I. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

565P Investigating highly differentiated cytotoxic T cells and functional severity in participants with inclusion body myositis in the INSPIRE-IBM trial.

Authors: Herrera, M. Wencel, M. Hernandez, I. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

542P INSPIRE-IBM: an NIH-funded, two-year, multicenter, observational study in inclusion body myositis (IBM)-an update.

Authors: Wencel, M. Goyal, N. Carbunar, O. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

541P Comparative evaluation of pulmonary function tests and self-reported respiratory function in inclusion body myositis based on NT5c1A antibody serology status.

Authors: Wencel, M. Bjazevic, K. Goyal, N. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

217P Comparing IBMFRS and sIFA as progression indicators in inclusion body myositis patients from the INSPIRE-IBM trial.

Authors: Gaid, P. Wencel, M. Hernandez, I. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

G.P.170 - Novel histopathological features in a patient with a novel mutation in DNAJB6 gene (LGMD 1D locus).

Authors: Iyadurai, S. Roggenbuck, J. Freimer, M.

Source: Neuromuscular Disorders. Oct2015 Supplement 2, Vol. 25, pS235-S236. 1p.

VP55 Topline data analysis of the phase 1/2 clinical trial evaluating AOC 1001 in adult patients with myotonic dystrophy type 1: MARINA.

Authors: Johnson, N. Day, J. Hamel, J. et al.

Source: Neuromuscular Disorders. 2023 Supplement 1, Vol. 33, pS69-S69. 1p.

SUSTAINED MINIMAL SYMPTOM EXPRESSION IN GENERALISED MYASTHENIA GRAVIS: A 120-WEEK POST HOC ANALYSIS OF RAISE-XT.

Authors: Marini, S. Bresch, S. Freimer, M. et al.

Source: Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases 2026 Supplement; Vol. 45.

Journal Info: Publisher: Mediterranean Society of Myology ISSN: 1128-2460

EARLY AND SUSTAINED RESPONSE OVER TIME WITH ZILUCOPLAN IN GENERALISED MYASTHENIA GRAVIS: 120-WEEK POST HOC ANALYSIS OF RAISE-XT.

Authors: Cheli, M. Bresch, S. Freimer, M. et al.

Source: Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases 2026 Supplement; Vol. 45.

Journal Info: Publisher: Mediterranean Society of Myology ISSN: 1128-2460

Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study.

Authors: Hussain Y Malhotra S Sperry BW et al.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2537347. Date of Electronic Publication: 2025 Sep 20.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase IV

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.

Authors: Freimer M Desai U Govindarajan R et al.

Source: Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2025 Jul 05; Vol. 18, pp. 17562864251347283. Date of Electronic Publication: 2025 Jul 05 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: SAGE Country of Publication: England NLM ID: 101480242 Publication Model: eCollection Cited Medium: Print ISSN: 1756-2856 (Print) Linking ISSN: 17562856 NLM ISO Abbreviation: Ther Adv Neurol Disord Subsets: PubMed not MEDLINE

Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.

Authors: Hewamadduma C Freimer M Genge A et al.

Corporate Authors: Hewamadduma C Freimer M Genge A et al.

Source: Journal of neurology [J Neurol] 2025 Jun 12; Vol. 272 (7), pp. 457. Date of Electronic Publication: 2025 Jun 12.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE

P.107 Early and sustained response over time with zilucoplan in generalised Myasthenia Gravis: 120-week post hoc analysis of RAISE-XT.

Authors: Blanchard, O Bresch, S Freimer, M et al.

Source: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2025 Supplement 1; Vol. 52 (S1).

Journal Info: Publisher: Cambridge University Press ISSN: 0317-1671